In a real-world cohort of patients with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer, efficacy and toxicity outcomes with olaparib maintenance therapy were consistent with findings observed in previous clinical trials, according to a poster presented at 2020 European Society of Medical Oncology (ESMO) Virtual Congress 2020.
“Olaparib was initially approved by the European Medicines Agency (EMA) as maintenance treatment for patients with BRCAm platinum-sensitive relapsed high-grade epithelial ovarian cancer, following the results of a randomized phase II trial (study 19),” researchers wrote. “The RETROLA study aimed to evaluate whether the outcomes observed in this clinical trial are reflected in routine clinical practice in a real-world cohort of patients.”
The RETROLA analysis included 128 patients across 28 centers in France. Researchers randomly selected and reviewed medical records for patients who started olaparib 400 mg twice a day, in capsule form, between March 2014 and March 2017.
The median progression-free survival in the study population was 15.5 months, and median overall survival was 33.6 months, according to the study. Focusing on the 89 patients treated in adherence to the EMA label, the median progression-free survival was 17 months.
Toxicity prompted olaparib discontinuation in 11.2% of patients, and 58.6% of patients had one or more dose reductions or interruptions, researchers reported. Five patients were diagnosed with related myelodysplastic syndrome and one patient with a second cancer.
Two or fewer previous lines of systemic therapy were associated with prolonged progression-free survival, according to the study.—Jolynn Tumolo
de La Motte Rouge T, Bengrine Lefevre L, Mouret-Reynier M-A, et al. Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: the GINECO RETROLA study. Abstract presented at ESMO Virtual Congress 2020. September 17, 2020. Abstract 823P.
